Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087269 · ClinicalTrials.gov registry record · Phase 2
Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT00087269: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00087269 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087269, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
This phase II trial is studying how well erlotinib works in treating patients with stage I, stage II, or stage IIIA non-small cell lung cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving erlotinib before surgery may shrink the tumor so that it can be removed.
Interventions
- OTHER laboratory biomarker analysis
- DRUG erlotinib hydrochloride
- PROCEDURE therapeutic endoscopic surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087269
The ClinicalTrials.gov registry entry for NCT00087269 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00087269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087269 about?
NCT00087269 is a clinical study titled "Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection". This phase II trial is studying how well erlotinib works in treating patients with stage I, stage II, or stage IIIA non-small cell lung cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving erlotinib before surgery may shrink the tumor so tha...
What is the current status of trial NCT00087269?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2004-12.
What interventions are being tested in trial NCT00087269?
The interventions under investigation include: laboratory biomarker analysis (OTHER), erlotinib hydrochloride (DRUG), therapeutic endoscopic surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00087269?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.